Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × ixazomib × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 13 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Mantle-Cell 2 Lymphoma, B-Cell 2 Immunoglobulin Light-chain Amyloidosis 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Proteostasis Deficiencies 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmablastic Lymphoma 1 Neoplasms, Plasma Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Chromosome 17 deletion 1 Carcinoma, Transitional Cell 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Amyloidosis 1 Alzheimer Disease 1

Interventions

Dexamethasone 24 Cyclophosphamide 21 venetoclax 17 fludarabine 12 Lenalidomide 12 Bortezomib 12 pembrolizumab 11 Cytarabine 11 Carboplatin 10 Calcium Dobesilate 10 Rituximab 8 pomalidomide 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 fludarabine phosphate 6 carfilzomib 6 selinexor 5 daratumumab 5 blinatumomab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 Bendamustine Hydrochloride 5 obinutuzumab 4 ibrutinib 4 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02343042 2025-12-22

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡